Omnicals Pharma Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Omnicals Pharma Private Limited Pharmaceutical Export Portfolio Dataset — 5 Products, $3.9M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Omnicals Pharma Private Limited — Pharmaceutical Exporter Profile (2026) | 5 Products, $3.9M Trade | TransData Nexus

Omnicals Pharma Private Limited

Indian Pharmaceutical Exporter · Tuberculosis Medications Specialist · $3.9M Total Trade · DGFT Verified

Omnicals Pharma Private Limited is an Indian pharmaceutical exporter with a total trade value of $3.9M across 5 products in 3 therapeutic categories. Based on 86 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Isoniazid ($1.4M), Rifampicin ($1.4M), Enoxaparin ($450.0K).

Omnicals Pharma Private Limited — Export Portfolio & Destination Treemap

Omnicals Pharma Private Limited pharmaceutical export portfolio — 5 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Omnicals Pharma Private Limited? — Company Overview & Market Position

Omnicals Pharma Private Limited, incorporated on May 17, 2017, is a privately held Indian pharmaceutical company headquartered in Mumbai, Maharashtra. The company is registered under the Corporate Identification Number (CIN) U33309MH2017PTC294976. Its authorized share capital is ₹10,000,000, with a paid-up capital of ₹2,075,000. The registered office is located at Flat No 43, Raheja Bldg, 2B Windermere, Oshiwara Link Road, Near Mhada, Lokhanwalla, Andheri West, Mumbai, Maharashtra 400053, India. The company specializes in the manufacture of medical, precision, and optical instruments, as well as watches and clocks, as per the National Industrial Classification (NIC) code 33309. As of March 2026, Omnicals Pharma employs approximately 44 individuals. The company's official website is www.omnicals.com.

What Does Omnicals Pharma Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Isoniazid$1.4M 2Rifampicin$1.4M

Product Portfolio — Top 5 by Export Value

Omnicals Pharma Private Limited exports 5 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Isoniazid	Tuberculosis Medications	$1.4M	29	0.1%	7
2	Rifampicin	Advanced Antibiotics	$1.4M	29	0.1%	6
3	Enoxaparin	Cardiovascular	$450.0K	9	0.2%	10
4	Pyrazinamide	Tuberculosis Medications	$275.2K	9	0.0%	9
5	Ethambutol	Tuberculosis Medications	$264.3K	10	0.0%	10

Omnicals Pharma Private Limited exports 5 pharmaceutical products across 3 therapeutic categories with a total export value of $3.9M. The top category is Tuberculosis Medications (51.2% of portfolio), followed by Advanced Antibiotics (37.3%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Omnicals Pharma Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Specific details regarding Omnicals Pharma's manufacturing facilities, including their locations, capacities, and specializations, are not publicly disclosed. The company's focus on manufacturing medical, precision, and optical instruments suggests that their facilities are equipped to produce high-quality pharmaceutical formulations. However, without access to proprietary information, a comprehensive assessment of their manufacturing capabilities cannot be provided.

3Key Leadership

The leadership team at Omnicals Pharma Private Limited comprises:

Anurag Bhoop Narayan Pathak: Managing Director, appointed on August 8, 2017.

Rohit Dansingh Negi: Director, appointed on May 17, 2017.

Anil Kashiram Fokmare: Director, appointed on December 15, 2022.

Nidhi Anurag Pathak: Director, appointed on May 3, 2023.

These individuals are responsible for steering the company's strategic direction and operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Omnicals Pharma Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Omnicals Pharma Private Limited's export data indicates a focus on tuberculosis medications, advanced antibiotics, and cardiovascular drugs. However, specific information regarding the company's regulatory filings, approvals, and market access status in the United States, European Union, United Kingdom, Australia, and Japan is not publicly available. The absence of such data suggests that the company may not have established a significant presence in these regulated markets. Without access to proprietary information, a detailed analysis of their regulatory standing in these regions cannot be provided.

2Emerging Markets

Omnicals Pharma's export data highlights a strong presence in tuberculosis medications, advanced antibiotics, and cardiovascular drugs. However, specific information regarding the company's penetration into African, Latin American, and Southeast Asian markets, as well as any WHO prequalification status, is not publicly available. The absence of such data suggests that the company may not have established a significant presence in these emerging markets. Without access to proprietary information, a comprehensive assessment of their market penetration and WHO prequalification status cannot be provided.

3Geographic Strategy

Omnicals Pharma Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific information regarding Omnicals Pharma's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The absence of such data suggests that the company may not have established a significant presence in the U.S. market. Without access to proprietary information, a comprehensive assessment of their FDA status cannot be provided.

2WHO & EU GMP

Specific information regarding Omnicals Pharma's WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, and European Directorate for the Quality of Medicines & HealthCare (EDQM) status is not publicly available. The absence of such data suggests that the company may not have obtained these certifications. Without access to proprietary information, a detailed assessment of their compliance with international quality standards cannot be provided.

3CDSCO & Indian Regulatory

Specific information regarding Omnicals Pharma's Central Drugs Standard Control Organisation (CDSCO) manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) is not publicly available. The absence of such data suggests that the company may not have obtained these regulatory approvals. Without access to proprietary information, a comprehensive assessment of their compliance with Indian regulatory requirements cannot be provided.

Omnicals Pharma Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Specific information regarding Omnicals Pharma's competitors in overlapping therapeutic categories, market share comparisons, and head-to-head analyses is not publicly available. The absence of such data suggests that the company may not have a significant presence in these markets. Without access to proprietary information, a comprehensive assessment of the competitive landscape cannot be provided.

2Key Differentiators

Omnicals Pharma's focus on global pharmaceutical business development and its partnerships with clients holding approvals from regulatory bodies such as the US FDA, UK MHRA, and Australian TGA indicate a commitment to quality and compliance. However, specific details regarding the company's unique strengths, competitive advantages, and product portfolio distinctions are not publicly available. Without access to proprietary information, a detailed analysis of their key differentiators cannot be provided.

3Strategic Position

Omnicals Pharma's export data indicates a focus on finished pharmaceutical formulations in critical therapeutic areas. However, specific information regarding the company's strategic direction—whether in generics, specialty drugs, biosimilars, or Contract Development and Manufacturing Organization (CDMO) services—is not publicly available. Without access to proprietary information, a comprehensive assessment of their strategic position and future outlook cannot be provided.

Buyer Due Diligence Brief — Evaluating Omnicals Pharma Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Omnicals Pharma's export data indicates a total export value of $3.9 million USD across 86 shipments, with a portfolio concentration of 100% in its top five products. This suggests a focused approach to its product offerings. However, specific information regarding the company's overall track record, export volume consistency, and reliability indicators is not publicly available. Without access to proprietary information, a detailed assessment of their supplier performance cannot be provided.

2Certifications to Verify

Importers should verify the following certifications when considering partnerships with pharmaceutical suppliers:

FDA Approval: Confirm the supplier's facility registration and product approvals through the FDA's official database.

WHO-GMP Certification: Verify the supplier's compliance with World Health Organization Good Manufacturing Practices by consulting the WHO's official listings.

Frequently Asked Questions — Omnicals Pharma Private Limited

How many pharmaceutical products does Omnicals Pharma Private Limited export from India?

Omnicals Pharma Private Limited exports 5 pharmaceutical products across 3 therapeutic categories. The top exports are Isoniazid ($1.4M), Rifampicin ($1.4M), Enoxaparin ($450.0K), Pyrazinamide ($275.2K), Ethambutol ($264.3K). Total export value is $3.9M.

What is Omnicals Pharma Private Limited's total pharmaceutical export value?

Omnicals Pharma Private Limited's total pharmaceutical export value is $3.9M, based on 86 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Omnicals Pharma Private Limited cover?

Omnicals Pharma Private Limited exports across 3 therapeutic categories. The largest are Tuberculosis Medications (51.2%, 3 products), Advanced Antibiotics (37.3%, 1 products), Cardiovascular (11.6%, 1 products).

Get Full Omnicals Pharma Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.